NCT06888050View on ClinicalTrials.gov

Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study

PHASE4RecruitingINTERVENTIONAL

Enrollment

268

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions

New-onset Type 2 Diabetes

Interventions

DRUG

henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ)

henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) (5mg/500mg, once a day, two tablets each time) plus lifestyle intervention

DRUG

Metformin

Metformin (500mg, twice a day) plus lifestyle intervention

Trial Locations (1)

310000

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors

collaborator

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY

lead

Zhejiang Provincial People's Hospital

OTHER